![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » Celgene elects Mark Alles and Jacqualyn Fouse
Celgene elects Mark Alles and Jacqualyn Fouse
February 12, 2016
Celgene has elected Mark Alles and Jacqualyn Fouse, Ph.D., to its Board of Directors.
Effective March 1, Alles will be promoted to chief executive officer, with Bob Hugin assuming the executive chairman role. Also effective March 1, Fouse will be promoted to President and COO.
Alles has been with Celgene since 2004, most recently serving as president and chief operating officer (COO). Before serving as president and COO, Alles led Celgene's Hematology and Oncology franchise.
Fouse has been with Celgene since 2010, most recently serving as president of Celgene's Hematology and Oncology franchise. Before serving as president of Celgene's Hematology and Oncology franchise, Dr. Fouse served as Celgene's chief financial officer.
"Mark and Jackie are extremely accomplished leaders who bring a wealth of experience and judgment to our Board," said Bob Hugin, chairman and CEO of Celgene. "Their strategic vision and knowledge of our business will be highly valued as we continue to guide Celgene's future."
Upcoming Events
-
21Oct